` 2315 (Biocytogen Pharmaceuticals Beijing Co Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2315
vs
Hang Seng (Hong Kong)

Over the past 12 months, has significantly outperformed Hang Seng (Hong Kong), delivering a return of 94% compared to the Hang Seng (Hong Kong)'s 39% growth.

Stocks Performance
2315 vs Hang Seng (Hong Kong)

Loading
2315
Hang Seng (Hong Kong)
Add Stock

Performance Gap
2315 vs Hang Seng (Hong Kong)

Loading
2315
Hang Seng (Hong Kong)
Difference

Performance By Year
2315 vs Hang Seng (Hong Kong)

Loading
2315
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Biocytogen Pharmaceuticals Beijing Co Ltd vs Peers

Hang Seng (Hong Kong)
2315
ABBV
AMGN
GILD
VRTX
Add Stock

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
6.1B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
9.4 HKD
Overvaluation 38%
Intrinsic Value
Price
B
Back to Top